# Cardiovascular Agents: Pulmonary Arterial Hypertension\*

**LENGTH OF AUTHORIZATIONS:**  365 Days

**GRANDFATHERING:**

Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the drug through the automated PA system. Patients who have taken the drug in the previous 120 days, but do not have claims history (e.g. new to Medicaid), will be approved for PA after prescriber contact.

**PRIOR AUTHORIZATION CRITERIA:**

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval?

    Acceptable reasons include:

    - Allergy to medications not requiring prior approval

    - Contraindication to all medications not requiring prior approval

    - History of unacceptable/toxic side effects to medications not requiring prior approval

2. Patients who have class 3 or 4 symptoms defined by the NYHA Functional Class for Pulmonary Hypertension may be approved for inhalation or intravenous agents
3. Riociguat (Adempas) may be approved for patients with persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) who have had surgical treatment or have inoperable CTEPH.
4. Has the patient failed a therapeutic trial of at least **30 days** with at least two medications, one of which is a Phosphodiesterase-5 Inhibitor, not requiring prior approval?

AR - Sildenafil oral solution: a PA is required for patients over 6 years old
